C
29.96
-0.03 (-0.10%)
Previous Close | 29.99 |
Open | 30.12 |
Volume | 1,512,845 |
Avg. Volume (3M) | 905,306 |
Market Cap | 2,806,655,488 |
Price / Sales | 3.40 |
Price / Book | 2.24 |
52 Weeks Range | |
Earnings Date | 6 Aug 2025 - 11 Aug 2025 |
Operating Margin (TTM) | -30,860.11% |
Diluted EPS (TTM) | -3.80 |
Quarterly Revenue Growth (YOY) | -43.60% |
Total Debt/Equity (MRQ) | 4.05% |
Current Ratio (MRQ) | 22.53 |
Operating Cash Flow (TTM) | -261.57 M |
Levered Free Cash Flow (TTM) | -155.77 M |
Return on Assets (TTM) | -20.13% |
Return on Equity (TTM) | -30.84% |
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Bearish | Bearish |
Biotechnology (Global) | Bearish | Bearish | |
Stock | Crinetics Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
1.8
Analyst Consensus | 2.0 |
Insider Activity | NA |
Price Volatility | 4.5 |
Technical Moving Averages | 1.0 |
Technical Oscillators | -0.5 |
Average | 1.75 |
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Core |
% Held by Insiders | 2.03% |
% Held by Institutions | 112.42% |
Ownership
Name | Date | Shares Held |
---|---|---|
Driehaus Capital Management Llc | 31 Mar 2025 | 6,239,902 |
52 Weeks Range | ||
Median | 81.00 (170.36%) | |
Total | 1 Buy |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
HC Wainwright & Co. | 27 Jun 2025 | 81.00 (170.36%) | Buy | 29.96 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |